Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

May 1, 2019

ZUG, Switzerland and CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the following investor conferences later this month:

SunTrust Robinson Humphrey 5th Annual Life Sciences Summit Date: Wednesday, May 8, 2019 Location: New York, NY

Bank of America Merrill Lynch 2019 Health Care Conference Date: Wednesday, May 15, 2019 Presentation: 1:00 p.m. PT Location: Las Vegas, NV

UBS Global Healthcare Conference Date: Tuesday, May 21, 2019 Presentation: 11:00 a.m. ET Location: New York, NY

A live webcast of the Bank of America Merrill Lynch and UBS events will be available on the “Events & Presentations” page in the Investors section of the Company’s website at https://crisprtx.com/events. A replay of the webcasts will be archived on the Company’s website for 14 days following each presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR Investor Contact:Susan Kim susan.kim@crisprtx.com

CRISPR Media Contact:Jennifer PaganelliWCG on behalf of CRISPR347-658-8290 jpaganelli@wcgworld.com